Standardized Brain Tumor Imaging Protocols for Clinical Trials: Current Recommendations and Tips for Integration

Overview

Journal Front Radiol

Specialty Radiology

Date 2023 Dec 28

PMID 38152383

Authors

Francesco Sanvito

Timothy J Kaufmann

Timothy F Cloughesy

Patrick Y Wen

Benjamin M Ellingson

Affiliations

Soon will be listed here.

Abstract

Standardized MRI acquisition protocols are crucial for reducing the measurement and interpretation variability associated with response assessment in brain tumor clinical trials. The main challenge is that standardized protocols should ensure high image quality while maximizing the number of institutions meeting the acquisition requirements. In recent years, extensive effort has been made by consensus groups to propose different "ideal" and "minimum requirements" brain tumor imaging protocols (BTIPs) for gliomas, brain metastases (BM), and primary central nervous system lymphomas (PCSNL). In clinical practice, BTIPs for clinical trials can be easily integrated with additional MRI sequences that may be desired for clinical patient management at individual sites. In this review, we summarize the general concepts behind the choice and timing of sequences included in the current recommended BTIPs, we provide a comparative overview, and discuss tips and caveats to integrate additional clinical or research sequences while preserving the recommended BTIPs. Finally, we also reflect on potential future directions for brain tumor imaging in clinical trials.

Citing Articles

Leptomeningeal metastatic disease: new frontiers and future directions.

Ozair A, Wilding H, Bhanja D, Mikolajewicz N, Glantz M, Grossman S Nat Rev Clin Oncol. 2024; 22(2):134-154.

PMID: 39653782 DOI: 10.1038/s41571-024-00970-3.

Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastoma.

Oshima S, Yao J, Bobholz S, Nagaraj R, Raymond C, Teraishi A CNS Oncol. 2024; 13(1):2415285.

PMID: 39535237 PMC: 11562955. DOI: 10.1080/20450907.2024.2415285.

Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma.

Jacome M, Wu Q, Pina Y, Etame A Cancers (Basel). 2024; 16(21).

PMID: 39518074 PMC: 11544870. DOI: 10.3390/cancers16213635.

"Synthetic" DSC Perfusion MRI with Adjustable Acquisition Parameters in Brain Tumors Using Dynamic Spin-and-Gradient-Echo Echoplanar Imaging.

Sanvito F, Yao J, Cho N, Raymond C, Telesca D, Pope W AJNR Am J Neuroradiol. 2024; 46(2):311-320.

PMID: 39242197 PMC: 11878977. DOI: 10.3174/ajnr.A8475.

Role of Magnetic Resonance Spectroscopy in Evaluating Choline Levels in Gallbladder Carcinoma: A Comprehensive Review.

Kumari A, Mishra G, Parihar P, Dudhe S Cureus. 2024; 16(8):e66205.

PMID: 39233932 PMC: 11374109. DOI: 10.7759/cureus.66205.

References

Ellingson B, Kim E, Woodworth D, Marques H, Boxerman J, Safriel Y . Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma. Int J Oncol. 2015; 46(5):1883-92. PMC: 4383029. DOI: 10.3892/ijo.2015.2891. View

Jaganmohan D, Pan S, Kesavadas C, Thomas B . A pictorial review of brain arterial spin labelling artefacts and their potential remedies in clinical studies. Neuroradiol J. 2020; 34(3):154-168. PMC: 8165894. DOI: 10.1177/1971400920977031. View

Manfrini E, Smits M, Thust S, Geiger S, Bendella Z, Petr J . From research to clinical practice: a European neuroradiological survey on quantitative advanced MRI implementation. Eur Radiol. 2021; 31(8):6334-6341. PMC: 8270851. DOI: 10.1007/s00330-020-07582-2. View

Shukla-Dave A, Obuchowski N, Chenevert T, Jambawalikar S, Schwartz L, Malyarenko D . Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials. J Magn Reson Imaging. 2018; 49(7):e101-e121. PMC: 6526078. DOI: 10.1002/jmri.26518. View

Almeida-Freitas D, Pinho M, Otaduy M, Braga H, Meira-Freitas D, da Costa Leite C . Assessment of irradiated brain metastases using dynamic contrast-enhanced magnetic resonance imaging. Neuroradiology. 2014; 56(6):437-43. DOI: 10.1007/s00234-014-1344-0. View

Ogura A, Hayakawa K, Miyati T, Maeda F . The effect of susceptibility of gadolinium contrast media on diffusion-weighted imaging and the apparent diffusion coefficient. Acad Radiol. 2008; 15(7):867-72. DOI: 10.1016/j.acra.2007.12.020. View

Smits M, Bendszus M, Collette S, Postma L, Dhermain F, Hagenbeek R . Repeatability and reproducibility of relative cerebral blood volume measurement of recurrent glioma in a multicentre trial setting. Eur J Cancer. 2019; 114:89-96. DOI: 10.1016/j.ejca.2019.03.007. View

Weber M, Thilmann C, Lichy M, Gunther M, Delorme S, Zuna I . Assessment of irradiated brain metastases by means of arterial spin-labeling and dynamic susceptibility-weighted contrast-enhanced perfusion MRI: initial results. Invest Radiol. 2004; 39(5):277-87. DOI: 10.1097/01.rli.0000119195.50515.04. View

Warntjes J, Dahlqvist Leinhard O, West J, Lundberg P . Rapid magnetic resonance quantification on the brain: Optimization for clinical usage. Magn Reson Med. 2008; 60(2):320-9. DOI: 10.1002/mrm.21635. View

10.

Shiroishi M, Castellazzi G, Boxerman J, DAmore F, Essig M, Nguyen T . Principles of T2 *-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging. J Magn Reson Imaging. 2014; 41(2):296-313. DOI: 10.1002/jmri.24648. View

11.

Ramakrishna R, Barber J, Kennedy G, Rizvi A, Goodkin R, Winn R . Imaging features of invasion and preoperative and postoperative tumor burden in previously untreated glioblastoma: Correlation with survival. Surg Neurol Int. 2010; 1. PMC: 2940100. DOI: 10.4103/2152-7806.68337. View

12.

Ellingson B, Lai A, Nguyen H, Nghiemphu P, Pope W, Cloughesy T . Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI. Clin Cancer Res. 2015; 21(19):4373-83. PMC: 4592379. DOI: 10.1158/1078-0432.CCR-14-2862. View

13.

Vogelbaum M, Brown P, Messersmith H, Brastianos P, Burri S, Cahill D . Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2021; 40(5):492-516. DOI: 10.1200/JCO.21.02314. View

14.

Kickingereder P, Wiestler B, Sahm F, Heiland S, Roethke M, Schlemmer H . Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging. Radiology. 2014; 272(3):843-50. DOI: 10.1148/radiol.14132740. View

15.

Elster A . How much contrast is enough?. Dependence of enhancement on field strength and MR pulse sequence. Eur Radiol. 1997; 7 Suppl 5:276-80. DOI: 10.1007/pl00006908. View

16.

Zhang J, Liu H, Tong H, Wang S, Yang Y, Liu G . Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges. Contrast Media Mol Imaging. 2017; 2017:7064120. PMC: 5612612. DOI: 10.1155/2017/7064120. View

17.

Song J, Kadaba P, Kravitz A, Hormigo A, Friedman J, Belani P . Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors. Neuro Oncol. 2020; 22(11):1658-1666. PMC: 7846197. DOI: 10.1093/neuonc/noaa066. View

18.

Ahn S, Taoka T, Moon W, Naganawa S . Contrast-Enhanced Fluid-Attenuated Inversion Recovery in Neuroimaging: A Narrative Review on Clinical Applications and Technical Advances. J Magn Reson Imaging. 2022; 56(2):341-353. DOI: 10.1002/jmri.28117. View

19.

Okada H, Weller M, Huang R, Finocchiaro G, Gilbert M, Wick W . Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015; 16(15):e534-e542. PMC: 4638131. DOI: 10.1016/S1470-2045(15)00088-1. View

20.

Henriksen O, Alvarez-Torres M, Figueiredo P, Hangel G, Keil V, Nechifor R . High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and Diffusion Techniques. Front Oncol. 2022; 12:810263. PMC: 8961422. DOI: 10.3389/fonc.2022.810263. View